A better understanding is needed concerning the risk factors and markers of disease progression in preclinical AD. In the Investigation of Alzheimer's Predictors in subjective memory complainers (INSIGHT-preAD) study, we aimed to investigate the relation between brain amyloidosis and various cognitive and neuroimaging parameters and the progression of cognitive decline in individuals with preclinical AD.
. Interpretation-Brain amyloidosis was not associated with differences in cognition and behaviour and it was not sufficient alone, even in this aged population, to define a high risk of rapid progression to a prodromal AD within 30 months. Follow-up is needed to establish whether this remains the case over longer periods.
Funding-IHU-A-ICM, Investissement d'Avenir from the Ministry of Research, Fondation Plan-
Alzheimer, Pfizer and AVID
RESEARCH IN CONTEXT

Evidence before this study
The PubMed Database and ClinicalTrials.gov were searched for the terms "Preclinical Alzheimer('s) disease", "Presymptomatic Alzheimer('s) disease", "Asymptomatic Alzheimer('s) disease" up to June 30th 2016, without any language restriction. This research was published in a recent 2017 systematic review. The same search strategy was further performed between June 2016 and the 4 th of July 2017 to include up to date published data. A meta-analysis on more than three thousand cognitively normal individuals, published in 2015, showed that amyloid PET positivity is a frequent finding even in the middle-aged population, in line with post-mortem studies. However, the longitudinal outcome of cognitively healthy individuals with markers of brain amyloidosis alone (ie, with negative tau or neurodegeneration markers) suggests that the risk of rapid progression to an overt clinical disease may not be high. At present, the natural history of these asymptomatic at risk subjects has not been completely elucidated. deep knowledge of the evolution of AD-related processes is absolutely needed for the successful design of the adequate clinical trials.
Added value of the study
We tested in a mono-center cohort of well-defined cognitively normal elderly participants with subjective memory complaints, whether brain amyloidosis, a mandatory marker of preclinical Alzheimer's disease, is associated to worse cognitive performances as well as brain atrophy on MRI and hypometabolism on Fluorodeoxyglucose PET in a multimodal analysis. We did not evidence any difference on these parameters at baseline and after a 24 months follow-up between amyloid positive versus negative participants after adjusting for age, gender, educational level. Using the occurrence of an amnestic syndrome of the hippocampal type as a clinically relevant marker of progression from preclinical to prodromal stage of AD , 4/88 (5%) A+ participants converted, giving an annual rate of 1.8%, while none of the 230 A-participants declined during the first 30 months of follow-up
Implications of all the available evidence
When strict inclusion criteria are used to warrant normal cognition in studies in preclinical AD, brain amyloidosis alone is not associated even to subtle cognitive changes. The annual rate of progression to a clinical diagnosis of AD of amyloid positive elderly with normal cognition is low in our study maybe in relation with their high educational level (mean 6.2, for a scale from 1 to 8 (max)). This is of major importance for clinical trials targeting preclinical AD and suggests that a large number of participants should be followed for more than 30 months to demonstrate clinical efficacy.
INTRODUCTION
During the last decade substantial progress has been achieved in the field of Alzheimer's disease (AD). Both the International Working Group (IWG) 1,2 and the National Institute on Aging-Alzheimer's Association (NIA-AA) 3, 4, 5 conceptualized the disease as a continuum, with the dementia syndrome representing the late end stage of a long period of cumulative pathological insults in the brain. This allowed for considering the preclinical stage of the disease, in which individuals free of cognitive and behavioural symptoms can now be identified by in vivo evidence of Alzheimer pathology 6 . The preclinical AD stage seems particularly important for interventions aiming at preventing progression to the clinical stage, as well as for research into novel biomarkers that might guide therapies with early disease modification. Amyloid brain lesions are necessary for the development of clinical AD, however they may not be sufficient. The progression to clinical AD can result from complex and specific interaction between influencing factors that may favour or decrease the disease progression. In parallel, it may be possible to identify markers of progression announcing or certifying further occurrence of clinical AD.
The objectives of the Investigation of Alzheimer's Predictors in subjective memory complainers (INSIGHT-preAD) study were to identify both the factors associated with and the markers of progression to clinical AD in asymptomatic at risk subjects. Working on these issues needs to use strict and clinically meaningful definitions of inclusion criteria and outcomes measures. To date, the use of cognitive composite scores to define preclinical AD progression and clinical expression raises the issue of the meaningfulness of these scores in practice, especially as the scores used vary from one study to another. 7, 8, 9, 10, 11, 12 INSIGHT-preAD was aimed at tackling these objectives by using evidence-based and clinically meaningful criteria for inclusion and outcomes in a group of 318 cognitively normal older individuals with a defined amyloid status. The follow-up of participants is on going. In this paper we analysed : i) the baseline data, comparing Amyloid positive (A +) and Amyloid negative (A -) subjects in order to investigate the impact of beta-amyloid deposition on several domains including subjective cognitive complaints, neuropsychological performance, fluid biomarkers, specific brain structures on volumetric MRI and regional metabolism on Fluorodeoxyglucose (FDG) -PET; ii) the evolution on all these parameters at month 24; iii) and the outcome for all participants at month 30 and the factors that may have influenced the progression in 4 participants.
METHODS
Study design and participants
INSIGHT-PreAD study (INveStIGation of AlzHeimer's PredicTors in subjective memory complainers) is a university expert memory clinic based mono-center observational cohort study conducted by the Institute of Memory and Alzheimer's disease, Pitié-Salpêtrière University Hospital, Paris. To be included, participants must meet the following criteria: age range between 70 and 85; presence of subjective memory complaints; normal Mini Mental State Examination 13 (MMSE≥27) and Clinical Dementia Rating 14 (CDR=0) scores; no evidence of episodic memory deficit as documented by a normal Free and Cued Selective Reminding Test score 15 (FCSRT; total score≥41); having visual and auditory acuity adequate for testing; and no systemic or chronic disease that may interfere with follow-up. The Ethic Committee of the Pitié-Salpêtrière Hospital approved the study protocol and all participants signed an informed consent form, previously explained and given (2 weeks before signature). The subjects were recruited through spontaneous consultation of all people referred at the memory clinic and through announcement of the study through press release and TV coverage. Study participants were recruited between May 25, 2013 and the last on January 20, 2015.
Procedures
Clinical, cognitive, psycho-behavioural and functional assessments (see Panel) were performed every 6 months by the same neuropsychologists (LB, MR, PR) and physicians (ADS, ML).
Brain amyloid PET scans were acquired 50 minutes after injection of 370 MBq (10 mCi) of 18F-Florbetapir 33 . Brain FDG-PET scans were obtained 30 minutes after injection of 2 MBq/kg of 2-deoxy-2-( 18 F)fluoro-D-glucose. Reconstructed images were analysed with a pipeline developed by the CATI (www.cati-neuroimaging.com) ( Supplementary Fig 1) . For amyloid PET images, standard uptake value ratios (SUVR) were calculated by averaging the mean activity of cortical regions of interest: both left and right precuneus, cingulum posterior, cingulum anterior, and parietal, temporal and orbitofrontal cortex.
The reference region was a combination of whole cerebellum and pons regions. The SUVR threshold to determine abnormality uptake was extracted performing linear correlation between our method 34 This strategy was previously used to study any relationships between different tracers or methods 37 .
The SUVr threshold of 0.7918 allowed a categorization of our population in Aß positive or Aß negative.
(More information are detailed in Supplementary data and Fig 2) . Neither the participants nor the investigators were aware of the amyloid status.
The same pipeline was applied to brain glucose metabolism PET images. Cortical metabolic indexes were calculated in four bilateral regions (posterior cingulate cortex, inferior parietal lobule, precuneus and inferior temporal gyrus), specifically affected by AD 38 with pons as reference region.
MRI acquisitions (1 hour duration) were performed on a 3T Siemens Magnetom VERIO MRI system (Siemens Medical Solutions, Erlangen, Germany). Scanning sessions included 3D T1-weighted magnetization-prepared rapid gradient echo (MP-RAGE), 2D FLAIR, 2D T2*, DTI acquisition and a T2*weighted gradient-echo echo-planar imaging scan series for use in the resting-state connectivity analysis and visual task, and a pulsed arterial spin labeling scan for measurement of cerebral blood flow at rest and visual task. Hippocampal volume was measured on 3DT1 sequence using the in-house SACHA software 39 and normalized to the mean total intracranial volume. Cortical thickness was measured in 68 regions of interest (ROI) of the Desikan-Killiany atlas using Freesurfer 5.3. EEG data were acquired using a 256-channel whole-head EEG System GES 300 (Electrical Geodesics Inc. EGI, Oregon, USA). High-density EEG was recorded: i) during rest while eyes were consecutively closed and open according to an audio cue for 30 s each and repeated twice; and ii) during a cognitive task-memory recall of words, which were previously memorized one hour before the recording with the FCSRT 15 .
CSF concentrations of total tau protein (t-tau), tau protein phosphorylated at threonine 181 (p-tau181) and amyloid-β peptide 1-42 (Aβ1-42) were analysed using the double antibody sandwich ELISA method (Innotest-Fujirebio ®, Courtaboeuf, France) 40 . The laboratory participates in the European External quality control program, provided by "The Alzheimer's Association QC program for CSF biomarkers" (http://neurophys.gu.se/sektioner/psykiatri_och_neurokemi/neurokem/theAlzAssQCprogram) 41 .
Genomic DNA was prepared from frozen blood samples using the 5Prime ArchivePure DNA purification system (Gaithersburg, MD) according to the manufacturer's instructions. APOE genotypes were determined for each individual using PCR-based Sanger sequencing. The amplified fragments were then purified and sequenced using the same primers (see Appendix).
All the subjects participate in a follow-up with clinical, cognitive, psycho-behavioural and functional assessments every 6 months, EEG and Actigraphy investigations every year, structural and functional MRI with resting state, FDG-PET and amyloid-PET scans every 24 months. The study will continue until the last participants to be enrolled into the trial have been followed for the prescribed 72 months.
MMSE and FCSRT scores below the threshold for inclusion in the study was indicative of a possible progression to clinical AD at a prodromal stage, defined by a positive amyloid PET and a persistent amnestic syndrome of the hippocampal type according to the IWG-2 criteria 41 . A low performance in one visit was not considered sufficient to ascertain a significant progression. In case of a persistent cognitive decline on two consecutive neuropsychological evaluations, an independent and blinded committee composed of two neurologists (BD, SE), a neuropsychologist (GG) and a neuroimaging expert (AB) reviews the medical file. All prodromal incident cases, consisting of an episodic memory deficit with a FCSRT Total recall below 41 together with a positive amyloid PET, therefore fulfilling IWG-2 criteria 42 , were further included in a clinical cohort with the same cognitive and neuroimaging investigations as those used in the INSIGHT study.
Statistical analysis
A sample size calculation was performed in order to get a sufficient degree of confidence around a positive likelihood ratio (LR+) and a negative likelihood ratio (LR-) 43 . The likelihood ratios incorporate both the sensitivity and specificity of the predictive model providing a direct estimator of how much the combination of predictors would change the odds of a progression to prodromal AD. Based on the figure of 14% of progression over 3 years reported by Rowe et al. in 2013 44 (data available when the study was designed) and based on the use of a 95% confidence interval (95%CI), 82 subjects are required.
Assuming a 8% permanent discontinuation rate during the study, enrolment was to be stopped when the number of 88 PET amyloid positive subjects has been reached.
Cognitive and behavioural tests scores, hippocampal volume, FDG-PET indexes and cortical thickness were compared between amyloid positive and negative subgroups. The t-test was performed on continuous data while the  2 test was utilized for categorical variables. A paired t-test was used for the comparison between right and left hippocampus volumes. For comparison between amyloid subgroups, linear models were used for continuous variables, Poisson models for discrete variables and logistic models for dichotomous variables in order to control for age, gender and education. FDG indexes were also adjusted for blood glucose. Tests in which a large number of participants scored zero were dichotomized in 0 vs non-0 categories. Group differences were tested using log-likelihood tests. P values were corrected for multiple testing using Benjamini-Hochberg correction. Missing data were not imputed. The same linear model generalized linear models were performed using the amyloid SUVR instead of amyloid group (Supplementary Table 3 ). Statistical analysis was performed using R 3.3.2.
Role of the funding source
None of the funders of the study participated in the design of the study, data collection, analysis, interpretation or in the writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
RESULTS
Out of the 363 successive screened subjects, 318 met the inclusion criteria (figure1). Table 1 shows the characteristics of INSIGHT-PreAD study participants at baseline with a mean age of 76.1 years (SD 3.47), a female predominance (63.2 %) and a high education level (mean 6.2; SD=2.1) for a scale from 1 to 8-max 34 . Their mean MMSE score was 28.67 (SD=0.96) and FCSRT total recall score was 46.09 out of 48 (SD=1.98). Participants had no deficit in any of the cognitive tests assessing memory, executive and instrumental functions. All the subjects were CDR=0 with a mean score at the FAB of 16.41 (± 1.68) and no naming difficulties (79.21 ± 1.11 out of 80 at the DO 80). Sixty-two subjects (20%) were APOE-ε4 carriers. The mean normalized hippocampal volume (left plus right) was of 2.71 cm3 (0.31), being significantly higher for the right hippocampus ( Table 1 ). The highest means of cortical metabolic activity in FDG PET were found in the right precuneus and parietal inferior region.
Concerning optional investigations, 51 subjects (27 men and 24 women) consented to lumbar puncture for AD biomarker investigation and 88 had an actigraphy at baseline.
Of the 318 subjects who underwent an amyloid PET investigation, 88 subjects (27.7%) were considered as positive (A+) (using the threshold of 0.79 -see methods) and 230 (72.3%) as negative (A-). 16/51 subjects who had a lumbar puncture (31%) were classified as (A+) and 45 (69%) as (A-) based on amyloid PET stratification. At baseline, as expected (Table 1 ) CSF Ab42 levels were lower and total tau and phosphorylated Tau were higher in (A+) compared to (A-) subjects (p<0.0001). Mean SUVr was significantly correlated with CSF Ab42 (r=-0.62, p<0.0001), and with CSF Ab40/Ab42 ratio (r = 0.61; p<0.0001). CSF Ab42 and CSF Ab40/Ab42 ratio discriminated A+ from A-subjects with high accuracy (AUCs= 0.89 [0.80-0.98] and 0.84 [0.72-0.96], respectively). A non-linear correlation was observed with Amyloid PET results, with the best correlation noticed in the lower range values of CSF Ab42 and in the parietal inferior and cingulate posterior areas ( Supplementary Fig 3) . A+ subjects were on average significantly older with a higher prevalence of APOE-ε4 carriers compared to the A-group (Table 1) . At baseline, no difference was found in terms of gender and education between the two groups. The two groups did not significantly differ in any other questionnaires assessing subjective feelings, behaviour, mood and quality of life. The number of subjects at each cognitive, behavioural and neuro-imaging investigation at baseline and at follow-up is given in supplementary Table S1. A+ participants showed significantly lower scores in MMSE and in FAB and a longer TMT B-A time ( Table 1 ). These differences disappeared when the results were adjusted for age, gender and education. There was no difference for the other cognitive tests, including the FCSRT total recall and the Memory Binding Test. There was no significant difference in regional metabolic imaging values between the amyloid-positive and amyloidnegative subgroups (table 1; supplementary table S3 ). A significant correlation was observed (p<0.05) between SUVr and FDG PET values in both cingulate posterior, precuneus and left parietal and temporal inferior regions, which disappeared after adjustment for age, sex and education (Table S3 ). On structural MRI, a significant decrease was observed at baseline in A+ subjects for each hippocampal volume, the difference remaining significant when adjusting for age, gender and education and correcting for multiple comparisons. Significant differences were observed in cortical thickness of the left temporal pole, left anterior cingulate (rostral) and right pars orbitalis that remained after adjustment for age, sex and education but disappeared after correction for multiple comparisons for the three cortical thickness measures (supplementary Table S2 ).
During the follow-up, the A+ participants did not differ from A-participants in any of the main cognitive tests assessing global efficiency (MMSE), episodic memory (FCSRT) and executive functions (FAB and TMTB-A); after 12 months and 24 months (see Table 2 ; results for all the tests will be reported separately). After 30 months, 274 subjects (out of whom 4 progressed to prodromal AD) were still in the study, 39 subjects have withdrawn (subject decision) and 5 deceased. Their performance remains stable over time ( Table 2 and normalized hippocampal volume for both sides and a mild executive dysfunction with a lower free recall score at the FCSRT and a lower FAB scores at baseline. By contrast they did not differ for the MMSE and the Total recall of the FCSRT. In each of the 4 cases, the progression began, in the year preceding prodromal AD by a severe drop in episodic memory: adjusting their cognitive performance to the group with Z scores, they all showed a significant decline of their Total Recall performance on the FCSRT episodic memory (10.75 for a mean decline of the population of 0.5) ( Table 2) .
DISCUSSION
In cognitively normal subjects with subjective memory complaints, with a mean age of 76 years, no difference in cognitive parameters was found between A+ and A-at baseline and after a 24 months follow-up and only 4 subjects progressed to a prodromal AD after 30 months. Compared to other ongoing cohorts 44 , the INSIGHT-preAD study presents substantial advantages. It is mono-centric, i.e. each subject being investigated by the same team of academic, expert neuropsychologists and by the same neuroimaging scanners, therefore substantially reducing variance of data and results. The normal cognitive status of each subject was formally confirmed at baseline and none of them had any evidence of an amnestic MCI based on the FCRST used for the first time as a screening tool in a cohort of people at risk of AD. This is an observational study with no intervention that may modify the follow-up and therefore affect statistical power. A large number of domains are investigated, including and objective measures of cognition and behaviour, different MRI and PET investigations and EEG with resting state and ERP. Among various psychometric methods, the high number of scales investigating the subjective feelings of the subjects and the carers may provide a unique opportunity to evaluate the impact of cortical beta-amyloid deposition on subtle cognitive or behavioural changes.
One of the main results at baseline is that only 28% of subjects with a mean age of 76 years were amyloid positive, a feature that is slightly below the picture of the main on-going multicentre studies [45] [46] [47] [48] [49] .
Reviewing the literature, 27% of subjects were considered as positive for amyloid PET in the main cross-sectional studies in preclinical AD ( 56;50;51 ) but this increases to 30.4% for studies when mean age is above 70 years (mean age of 74.4) according to our previously published systematic review on the cohorts used to study preclinical AD 44 ( Supplementary Table S4 ). The comparison between A + and Ashowed several differences at baseline for MMSE, tests of executive functions and hippocampal volume, significance that disappeared after adjustment for age and correction for multiple analyses. This underlines the necessity to control for the confounding effect of age, known to on executive functioning 52 and hippocampal volume 53 . It is noteworthy that: i) in all the published studies on cognitive decline in A+ subjects, these participants are always significantly older than the A-subgroup [7] [8] [9] [10] [11] and ii) that the decline occurs late, after at least 18 months of follow-up 8 . In sum, our results suggest that cortical betaamyloid deposition have no effect on cognitive, functional and behavioural domains.
The degree of cognitive complaints between A + and A -subjects were similar. All the subjects must have had some memory complaints to be included, but those who were A + did not complain more, suggesting that the intensity of subjective memory complaints may not be a strong candidate marker of preclinical AD as already shown in AIBL aging study 54, 55 . Moreover, the presence of amyloid brain lesions was associated with a low cognitive awareness in our participants. 34 This result may appear in contradiction with some recent data 56 but it is noteworthy that the subjects were only complainers and did not fully correspond to the definition of subjective cognitive decline 57 . However, an extensive investigation of their subjective feelings was performed, and to our knowledge, INSIGHT-preAD is the first study with such a comprehensive evaluation of different aspects of cognitive complaints, including 6 questionnaires with a total of 88 items all of which administered with the same investigators in participants who were cognitively healthy at study entry.
The overall cognitive performance does not decline over time for the whole group and for the A + subgroup after exclusion of the 4 progressors (Table 2 ). This surprising result suggests that age-related changes in A-subjects on the one hand and cortical beta-amyloid deposition in the A+ subjects on the other hand are either not severe enough to impact cognitive functioning or are compensated by brain changes and/or reserve. The increase of resting-EEG alpha oscillations with a stronger change in frontal activation over a period of 2 years in the A+ subgroup (p < 0.03) is in favour of a possible cognitive control compensation 58 (figure 2). These changes indicate that EEG is able to capture the neuronal dynamics associated with the beginning stages of brain amyloidosis and over time. To conclude, the fact that cognitive performance remains stable in the A+ participants and that they marginally benefit from a practice effect (see Table 2 ) favour the hypothesis of a compensated state in asymptomatic at risk subjects (decoupling between structural lesions and maintenance of cerebral functioning) that precedes the decompensation in a clinical disease rather than a slow decline in a progressive continuum with no clear barriers between the asymptomatic and symptomatic states 7,9 (see figure 3 ).
Strict inclusion criteria, short delay of observation, exclusion for the analysis of those subjects who further progressed to prodromal AD, and adjustment for age difference between subgroups (A+ vs A-) may explain the absence of decline.
The rate of progression to a clinically defined AD is surprisingly low despite the mean age of 77 year-old for the A + subjects. The follow-up is still on-going and the number of progressors might increase during further analyses according to a recent estimate of prevalence 59 . However, the number is low and may result from a possible selection bias. For agreeing to participate in this observational study with a heavy follow-up including several hours of cognitive, behavioural, and functional investigations and several PET and MRI scans, the subjects must have a certain degree of cultural level and interest in supporting research, which is confirmed by their high mean level of education. We may postulate that their cognitive reserve compensated for the effect of brain amyloid lesions and has delayed the entrance in a clinical disease. The analysis of these 4 cases raises the question of the factors that may have facilitated the disease progression. At baseline, they were older, with a higher beta-amyloid deposition, frequently ApoE-ε4 allele carriers, with an evidence of a mild executive dysfunction suggesting saturation of functional mechanisms. By contrast they did not differ from the rest of the participants for the MMSE and the Total recall of the FCSRT. During the follow-up, the onset of a severe drop in total recall performance during the preceding year is a marker of an on-going progression to a prodromal AD.
ApoE4 was also a strong predictor of rapid progression to clinical AD in A+ subjects (3.24% per year [3/37 in 2.5 years]) compared to non-ApoE4 carriers (0.78% per year [1/51 in 2.5 years]).
Taken together, these data suggest that cortical amyloidosis may be relatively clinically silent for a long period of time (see figure 3 ). It is only when a progression to a prodromal AD is on-going that episodic memory disorders appear, probably in relation with the activation of tau pathology at the level of medial temporal lobe structures. However, the rate of progression at 2.5 years remains weak in our study and in accordance with data from other follow-up studies on preclinical AD 48; 8;11 . These data are important with respect to on-going and future clinical trials on preclinical subjects, because the demographic characteristics of the randomized subjects will probably be similar with the same bias of selection. In that case, there is a need to increase considerably either the number of subjects or the duration of the trials as this is the case for instance in the A4 and Tommorrow ongoing studies (1150 and 3494 participants respectively, followed for almost 5 years) 60;61 . This also underlines the need to determine the associated factors that influence the decline such as age, ApoE status and initial amyloid burden among others. Besides the short follow-up so far, another limitation of our study is the censoring effect due to the inclusion criterion of age over 70 years old. Another related issue is to define new markers of disease progression that are less rigid. If the onset of a prodromal AD is indisputably a formal outcome for the study of efficacy of a disease modifier, it would be interesting to identify some surrogate markers that predict such an event before its occurrence and that may help to distinguish the progressors from those A+ subjects that remain stable over time. Our analysis of patients who converted to a prodromal AD suggests that a recent decrease in cued recall performance may be a marker of progression. This is not surprising as it indicates a progression of brain AD lesions. The next follow-up of the study should help to confirm whether this effect is consistent..
In the field of disease-modifying therapies, there is an upcoming trend to shift from AD dementia stages to the early prodromal stages. It will be crucial to define clearly the dynamic processes that precede the progression to a clinical disease. The INSIGHT-preAD study, designed for identifying the best multimodal biomarkers combination for predicting the secondary occurrence of clinical AD, will constitute a valuable repository of clinical, cognitive, neuroimaging, neurophysiological, and biological data to be shared with the scientific community. Our data suggest that brain amyloidosis has no impact on behaviour and cognition at baseline and after a follow-up of 30 months suggesting that compensatory mechanisms are present for maintaining a normal brain functioning and that amyloidosis alone is not sufficient to define a high risk of rapid progression to a clinical AD.
Panel: Assessments used in INSIGHT-PreAD
Subjective feelings about memory and cognition (more information in the supplementary data) 
15-item version of the
Psycho-behaviour, mood, autonomy and quality of life
Neuropsychiatric Inventory (NPI) 18 State-Trait-Anxiety Inventory Y (STAI-Y-B) 19 Geriatric Depression Scale (GDS) 20 
Starkstein Apathy Scale 21
Bristol Activities of Daily Living (Bristol ADL) 22 Amsterdam IADL Questionnaire EuroQol 5D test (EQ-5D-3) 23 Memory Binding Test (MBT) 26 For working memory and executive functions:
Cognitive functions
Forward and backward Digit and Visuo-spatial span 27 Frontal Assessment Battery (FAB) 28 † Trail Making Test (TMT) 29 † Lexical Fluency (P words in 2 minutes) 30 For instrumental functions Semantic Fluency (animals in 2 minutes) 30 Image Naming (DO 80) 31 Praxis assessment 32 Rey-Osterrieth Complex Figure ( 
Neural dynamics EEG with resting state and ERP
High-density EEG during rest
High-density EEG during a cognitive task-memory recall of words CSF biomarkers total tau protein (t-tau), tau protein phosphorylated at threonine 181 (p-tau181) amyloid-β peptide 1-42 (Aβ1-42)
ApoE genotyping
All assessments were done at baseline. All participants have neuropsychological assessment, EEG and actigraphy every 12 months, and blood sampling MRI, FDG-PET, and amyloid-PET scans every 2 years. Here, we report baseline data for all variables except for Amsterdam IADL, which will be presented in a separate paper. † For 12 and 24 months we present results of main cognitive tests assessing cognitive global efficiency (MMSE), episodic memory (FCSRT) and executive functions (FAB and TMTB-A), with other test results to be reported in more detail in subsequent follow-up reports.
* Information can be found in Reference 34
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-Image analysis
PET images were analysed with an in-house pipeline developed by the CATI (http://catineuroimaging.com), including partial volume effect correction (PVEC), on untransformed PET images, to reduce possible quantification biases related to spatial normalization or co-registration. Supplementary Figure 1 shows the different processing steps implemented.
MRI 3D T1-weighted images were segmented and spatially normalized into the MNI space using the VBM8 package (http://dbm.neuro.uni-jena.de/vbm/) implemented in SPM8. Deformation fields and grey and white matter masks were generated. Structural MRI images were co-registered to PET images using SPM8 with visual inspection to detect any co-registration errors. Using inverse deformation fields and matrix transformation, composite cortical regions of interest (ROIs) and a reference region were placed in the individual native PET space. We then applied a PVEC algorithm that performs a region- 
